Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06061796
Other study ID # APHP230672
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 18, 2024
Est. completion date May 18, 2025

Study information

Verified date January 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Jean Damien Ricard, MD/PHD
Phone 01 47 60 61 62
Email jean-damien.ricard@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ARDS is an acutely induced respiratory failure characterized by the appearance of bilateral alveolar opacities on imaging and hypoxemia Etiologies are divided into two classes: pulmonary, including all infectious pathologies, aspiration pneumonia, and drowning, and extra-pulmonary, induced by sepsis or acute pancreatitis. The mortality rate of ARDS remains high in unselected patient populations Among strategies that have proven beneficial in terms of patient outcome, prone positioning (PP) is associated with the greatest impact in terms of reduction in mortality. PP is currently recommended in the European guidelines for ARDS associated with a PaO2/FiO2 ratio < 150 mmHg in patients in whom ventilatory settings have been optimized beforehand, The failure of early PP studies to demonstrate a survival benefit in ARDS was attributed to insufficient session duration. The PROSEVA study was the first to demonstrate that a PP duration of 17 h is associated with a reduction in mortality During the COVID-19 pandemic, several centers have reported the implementation of longer PP sessions. Two strategies have emerged from these studies. In one case, the patient was left in the prone position until the criteria for stopping PP were met. Thus, the PP/supine position alternation was completely suppressed. In another published strategy, PP sessions were maintained for a period covering two nights. Furthermore, in a multicenter retrospective study, PP sessions were maintained until clinical improvement was associated with reduced mortality. In this study of 263 patients, the median duration of PP in the extended duration group was 40 h, and 75% of the sessions lasted 48 h or less. Using a propensity score, the authors showed that patients treated with an extended PP duration had a lower 3-month mortality rate than patients in the standard duration group . This protocol was also associated with a 29% cumulative incidence of pressure sores, similar to the 25% cumulative incidence reported in the PROSEVA study Other data published on pressure sores and PP of duration > 24 hours are also reassuring. Finally, a recent review recently reported that an extended PP session of > 24 h had also been used before the COVID-19 pandemic. PP sessions had a median duration of 47-78 hours and were applied mainly to ARDS secondary to community-acquired pneumonia. All pre-COVID studies were retrospective, monocentric, without a control group.


Description:

Description of procedures performed according to standard of care: Patients will be ventilated with a tidal volume of between 6 and 8 ml/kg ideal body weight. FiO2 will be set to target oxygen saturation between 92 and 96%. Patients will be curarized. The positive end-expiratory pressure (PEEP) will be set at least at 8 cm H2O, and a PEEP trial will be performed to find the best compromise between being slightly below maximum lung compliance, maximizing oxygenation, minimizing hemodynamic effects, and maintaining a plateau pressure strictly below 30 cm H2O. Patients will be turned in the prone position, with a cushion placed transversely opposite the shoulders and thorax, to relieve the neck and abdomen of any overpressure. The pressure points will be protected. The protocol complies with the recommendations of the Intensive Care Society and the Faculty of Intensive Care Medicine. The response to PP will be assessed by taking an arterial blood gas before PP, after 16 hours of PP, just before return to the supine position and 4 hours after the return to the supine position. In the event of a P/F ratio below 80 mm Hg, inhaled nitric oxide (iNO) will be added. In the event of non-response to iNO in terms of PaO2, the use of extracorporeal membrane oxygenation (ECMO) will be discussed. Patients will also benefit from etiological treatment specific to the underlying pathology. Finally, pressure sores are prevented through daily care and the use of anti-sore mattresses. Regular repositioning and daily skin assessment will be carried out by a nurse. Description of procedures added by the research protocol Two procedures will be added to this usual patient management procedure. Patients will be maintained in PP until all the following criteria have been met for 4 consecutive hours: P/F ratio > 150 mm Hg, FiO2 < 60%, PEEP ≤ 10 cm H2O. We also impose a minimum session duration of 16 hours and a maximum session duration of 48 hours. Following this first session, if PP sessions are still indicated, for example in case of mechanically ventilated acquired pneumonia (MVAP), these sessions will be carried out according to the usual protocol, with sessions maintained for 16 to 24 hours, alternating with 8-hour periods in dorsal decubitus. The criteria for stopping this PP / supine alternation will be the usual ones: P/F < 150 mmHg with FiO2 < 60% and PEEP ≤ 10 cm H2O. The second procedure added by the research is ventilation monitoring with the Dräger PulmoVista 500 electrical impedance tomography (EIT). This monitoring will only be carried out during the first prone session. Two sets of sixteen electrodes will be placed around the patient's thorax. These electrodes will capture 50 images per second, reflecting variations in pulmonary electrical impedance as a function of ventilation. The data will be recorded during 4 successive sessions: one before turning the patient on the prone position, one at H+16 after PP started, one before being turned back to the supine position and one 4 hours after being turned back in the supine position. The raw signals will be extracted from the EIT and analyzed using dedicated external software. Summary of the main benefits and expected risks associated with the protocol The main benefits expected for the patient are: - The pursuit of a more homogeneous distribution of lung ventilation volumes associated with fewer overdistended pulmonary units, atelectatic pulmonary units and pulmonary units opening and closing cyclically. - Delayed derecruitment induced by return in the supine position after a PP session. - In the event of acute right heart failure, prolonged PP session is likely to further allow the unloading of the right ventricle. - possibly reduced mortality The main risk associated with this procedure is the potential increase in the incidence of pressure sores. Our published data are rather reassuring on this subject and show that increasing the duration of all PP sessions to a median duration of 40 hours is associated with a 2.5% cumulative incidence of grade ≥ III pressure sores, a cumulative incidence of pressure ulcers grade ≥ II of 26%, which was no greater than the cumulative incidence of 25% reported in the PROSEVA ancillary study. Finally, the main risk factor for pressure sores is not so much the duration of individual sessions as the cumulative duration. Other risks include: - a deterioration in the homogeneity of ventilatory volume distribution, with a re-increase in the percentage of atelectatic pulmonary units, over-distended pulmonary units and pulmonary units opening and closing cyclically. - in the event of cardiac arrest, cardiac massage is delayed by the need to return the patient in the supine position before cardiopulmonary resuscitation can be started Course of research Inclusion visit At the inclusion visit, the patient will be intubated and mechanically ventilated. The indication for ventilation in the prone position will have been established but will not have been turned in the prone position yet. Demographic variables and patient history (COPD, pulmonary emphysema, asthma, etc.) will be collected. A clinical examination will also be carried out on the patient to ensure that there are no pressure sores. Monitoring by EIT will be initiated once the ventilator parameters have been stable for 20 minutes. All the ventilator's anonymized data will be retrieved on an encrypted external hard disk. Afterwards, the patient will be placed in the prone position. Research follow-up visits At least four follow-up visits will be organized: 1. One between H+12 and H+24 after the start of PP, trying to be as close as possible to H+16. 2. One just before return in the supine position 3. One between one and four hours after return in the supine position 4. One on the day of discharge or death. In the event of a subsequent indication to be returned to the supine position, a visit will be made after each return to the supine position. During the first three visits, the same information and complementary examinations will be carried out: monitoring by electrical impedance tomography with initial ventilation parameters and during a long inspiratory time. All anonymized ventilator data will be retrieved on an encrypted external hard disk. At the 3rd follow-up visit, i.e. between H+1 and H+4 after the patient has been put back on his back, we will note the exact date and time when the patient was put back in the supine position, and whether the patient was curarized, put on NO, put on ECMO or put on norepinephrine at any time during the PP session. If one of these interventions was carried out, we'll note the start and end times. Finally, we'll check whether the patient has any pressure sores. After this first PP session, if subsequent sessions are indicated, the patient will be examined after each return to the supine position, and any pressure sores will be recorded. End-of-research assessment During the end-of-research visit, complete information on the patient's care in the intensive care unit will be collected. If the patient has not died, we will record whether he or she has brachial plexus or pressure sore damage. The doctor in charge of the patient in intensive care will be responsible for the various visits. Method for collecting efficacy assessment parameters: The distribution of ventilatory volumes during PP sessions will be performed using an electrical impedance tomograph (EIT). The EIT used will be the Dräger PulmoVista500, consisting of two 16-electrode belts. The EIT measures variations in electrical impedance in different areas of the lung by sending electrical pulses at a speed of 50 Hz. This variation in electrical impedance is proportional to the variation in ventilation of the zones in question. So, the greater the delta in ventilation of a lung zone between the end of inspiration and the end of expiration, the greater the variation in its impedance. The PulmoVista is set to a recording speed of 50 Hz. The filter for suppressing low-frequency signals and the high and low limits of the bandwidth filter will be set individually for each patient to personalize image quality. To limit the noise associated with patient mobilization and changes in ventilatory parameters, the electrode belt should be installed 20 minutes before each series of measurements. Similarly, before each series of measurements, ventilatory parameters should have been stable for 20 minutes. The variation in electrical impedance will be recorded by the EIT for 5 minutes. The inspiratory time is then increased by decreasing the respiratory flow to 10 L/min, the respiratory frequency to 15/min and reducing the ratio of inspiratory time to expiratory time to 1:1. Immediately afterwards, the EIT parameters are recorded for 5 minutes and then the ventilator parameters are reset to their initial values. Methodology This is a prospective, bicentric, cohort study. The two recruiting centers will be: - The intensive care station of Louis-Mourier university hospital in Colombes, part of the greater Paris Hospital, chief of station: Pr Jean-Damien Ricard. - The intensive care station of Saint-Antoine university hospital in Paris, part of the greater Paris Hospital, chief of station: Pr Eric Maury. The inclusion period will last a maximum of 12 months. Depending on the length of ICU stay, the total duration of the study will be maximum 14 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date May 18, 2025
Est. primary completion date January 18, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patient with with ARDS with a P/F ratio < 150 mm Hg regardless of etiology - invasive ventilated patient - indication for DV placement determined by the treating practitioner - BMI= 18 kg/m² - Affiliated to social security Exclusion Criteria: - Patients who have already undergone two prone position sessions - Pregnant women - Refusal to participate in the research - Patients under guardianship and trusteeship - Patients under State Medical Assistance (AME) - Uncontrolled intracranial hypertension - Unstable spinal fracture - Hemodynamic instability defined by MAP < 65 mmHg - Presence of a pacemaker - Presence of an implantable defibrillator - Unresolved pneumothorax or bronchopleural fistula

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
prone position
patient kept in prone position until the following criteria have been reach for 4 consecutive hours: ratio P/F > 150 mm Hg FiO2 < 60% PEEP = 10 cm d'H2O

Locations

Country Name City State
France Louis Mourier Hospital Colombes

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Distribution of intra-pulmonary ventilation volumes during PP sessions maintained until clinical improvement and for a maximum of 48 hours. The primary endpoint is the center of lung ventilation measured by the EIT between H+16 and before return in the supine position.
This index approximates the proportion of ventilation attributable to the dorsal pulmonary units. It is calculated as follows:
CVP(%)= ((?Z at the level of dorsal pulmonary units)*100)/(?Z in the whole lung)
Where CVP means the center of alveolar ventilation and ?Z means the variation in electrical impedance during the ventilatory cycle.
EITmeasurements between H+16 and before return in the supine position
Secondary Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of the percentage, of the percentage of over-distended pulmonary units The evaluation end point is the percentage of overdistended alveoli and is defined as overdistended pixels on the image produced by the EIT, i.e. as pixels being aerated at the end of expiration but not ventilated, EITmeasurements between H+16 and before return in the supine position
Secondary Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of the percentage of pulmonary units opening and closing with each respiratory cycle The evaluation end point is the percentage of pixels opening and closing cyclically at each inspiratory cycle, i.e. pixels ventilated but not aerated at the end of expiration. EITmeasruements between H+16 and before return in the supine position
Secondary Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of the percentage of collapsed pulmonary units The evaluation end point is the percentage of pixels opening and closing cyclically The evaluation end point is the percentage of pixels for which the variation in electrical impedance is less than 10% of the maximum variation found among all pixels during a respiratory cycle. EIT measurements between H+16 and before return in the supine position
Secondary Evaluation during a PP session maintained until clinical improvement and for a maximum of 48 of percentage of recruitable pulmonary units The evaluation end point is the percentage of recruitable pixels will be estimated using the regional ventilation delay (RVD) index as defined in Wriggle et al 2008 CCM and corresponding to : RVD= t_10%*?Z/?t Where t_10% is the time in seconds required to reach 10% of the maximum variation in electrical impedance of the pixel considered for a respiratory cycle, ?Z is the maximum variation in electrical impedance during the respiratory cycle and ?t is the time in seconds of the inspiratory cycle. EIT measurements between H+16 and before return in the supine position
Secondary Evaluation of the association between prolonged PP duration and the incidence of pressure sores Pressure sores will be assessed daily for as long as the indication for PP ventilation persists. In the event of pressure sores, their grade will be assessed using the Revised Pressure Injury Staging System. The last day in ICU
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A